IL6 as prognostic factor for severity of COVID-19

Aseel Hamzah Noori; Mohammed Hasan Ali

doi:10.53730/ijhs.v6nS9.14027

Authors

Aseel Hamzah Noori
dr.ahn1977alkhawaja@gmail.com
Babylon College of Medicine/University of Babylon, Babylon, Iraq
Mohammed Hasan Ali Babylon College of Medicine/University of Babylon, Babylon, Iraq

Keywords:

IL-6 levels, COVID-19 patients, hematological and serological markers

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the viral illness known as coronavirus disease 2019. Several inflammatory and biochemical markers are elevated, and blood indices are altered, in COVID-19, a sign of a cytokine storm.(50) COVID-19 patients at Marjan medical city and Imam Sadiq Teaching hospitals between December -2021 and April -2022 were studied for the connection of IL-6 levels. Results of blood tests varied significantly depending on the severity of the condition. Interleukin-6 (IL-6) and SPO2 (percent) were significantly different between the two measurement periods at day 1 and day 3. Nearly three out of four patients had severe illness (N=34, 68.0 percent), and there was no one with moderate disease (N=16, 32.0 percent). According to the level of illness severity, there were large variations in the distribution of age groups. This study found a strong correlation between illness severity and immunization history and previous medical records.

Downloads

Download data is not yet available.

References

Abady, N. R., Al-Khafaji, Z. A., & Baay, A. S. (2022). Clinical features associated with Severe Acute Respiratory Syndrome (SARS-COV2). International Journal of Health Sciences, 6(S1), 5679–5688. https://doi.org/10.53730/ijhs.v6nS1.6239

Akira, S., Taga, T., & Kishimoto, T. (1993). Interleukin-6 in biology and medicine. Advances in immunology, 54, 1-78

Al-Khafaji, Z., N. Abady, and H. Al-Kafaji, Epidemiological and Clinical Comparative Study for COVID-19 Patients in Babylon Province, Iraq. Archives of Razi Institute, 2022. 77(1): p. 101-105.

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., ... & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet, 395(10223), 507-513

Delerive, P., De Bosscher, K., Besnard, S., Berghe, W. V., Peters, J. M., Gonzalez, F. J., ... & Staels, B. (1999). Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. Journal of Biological Chemistry, 274(45), 32048-32054

Diao, B., Wen, K., Chen, J., Liu, Y., Yuan, Z., Han, C., ... & Wu, Y. (2020). Diagnosis of acute respiratory syndrome coronavirus 2 infection by detection of nucleocapsid protein. MedRxiv.

Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., ... & Zamboni, M. (2011). Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. Journal of the American Medical Directors Association, 12(4), 249-256

Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V., Yudkin, J. S., Humphries, S., & Woo, P. (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. The Journal of clinical investigation, 102(7), 1369-1376

Hashizume, M., Hayakawa, N., & Mihara, M. (2008). IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology, 47(11), 1635-1640

Heinrich, P. C., Castell, J. V., & Andus, T. (1990). Interleukin-6 and the acute phase response. Biochemical journal, 265(3), 621

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497-506.

Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., ... & Manolagas, S. C. (1992). Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science, 257(5066), 88-91

Kimura, A., & Kishimoto, T. (2010). IL‐6: regulator of Treg/Th17 balance. European journal of immunology, 40(7), 1830-1835

Kotake, S., Sato, K., Kim, K. J., Takahashi, N., Udagawa, N., Nakamura, I., ... & Kashiwazaki, S. (1996). Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation. Journal of Bone and Mineral Research, 11(1), 88-95

Libermann, T. A., & Baltimore, D. (1990). Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Molecular and cellular biology, 10(5), 2327-2334

Magro, G. (2020). SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the'culprit lesion'of ARDS onset? What is there besides Tocilizumab

Noor Abady, Zaytoon A Alkhafaji, Ali Saleh Baay [2] Genetic Detection and Phylogenetic Tree Study for SARS COV-2 (N Gene) In Iraq. Journal of Complementary Medicine Research, 12 (4), 131-135. doi:10.5455/jcmr.2021.12.04.20

Noor. R. A., zaytoon. A & Baay, . A. s. (2022) Detection of missense and frame shift mutations in envelope proteins using molecular phylogenetic SARS-COV-2. Journal of Complementary Medicine Research, 13 [2], 92-97. doi:10.5455/jcmr.2022.13.01.17

Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., ... & Costantini, F. (1994). Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion. The EMBO journal, 13(5), 1189-1196.